This Supplement (the “Supplement”) to the base prospectus dated July 29, 2022 (the “Original Base Prospectus”), as supplemented by the 1st Supplementary Prospectus dated August 31, 2022, the 2nd Supplementary Prospectus dated December 6, 2022 and the 3rd Supplementary Prospectus dated December 20, 2022 (the Original Base Prospectus and together with the 1st Supplementary Prospectus dated August 31, 2022, the 2nd Supplementary Prospectus dated December 6, 2022 and the 3rd Supplementary Prospectus dated December 20, 2022, the “Base Prospectus”) which comprises a base prospectus under Article 8 of Regulation (EU) 2017/1129 (as amended, the “Prospectus Regulation”) for Royal Bank of Canada (“RBC”, the “Bank” or the “Issuer”), constitutes a supplementary prospectus in respect of the Base Prospectus for RBC for the purposes of Article 23.1 of the Prospectus Regulation and is prepared in connection with the Programme for the Issuance of Securities established by RBC.

This Supplement has been approved by the Central Bank of Ireland as Irish competent authority under the Prospectus Regulation. The Central Bank only approves this Supplement as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Bank as an issuer, nor as an endorsement by the Central Bank of Ireland of the quality of Securities that may be issued under the Programme. Investors should make their own assessment as to the suitability of investing in such Securities.

Such approval relates only to the Securities which are to be admitted to trading on the regulated market of the Irish Stock Exchange plc trading as Euronext Dublin (“Euronext Dublin”) or other regulated markets for the purposes of Directive 2014/65/EU (as amended) and/or which are to be offered to the public in any member state of the European Economic Area in circumstances that require the publication of a prospectus.

The Issuer produced listing particulars dated July 29, 2022, as supplemented by the 1st Supplementary Prospectus dated August 31, 2022, the 2nd Supplementary Prospectus dated December 6, 2022 and the 3rd Supplementary Prospectus dated December 20, 2022 (together, the “Listing Particulars”) for the purposes of listing on the Global Exchange Market of Euronext Dublin. The Listing Particulars do not constitute a “prospectus” for the purposes of the Prospectus Regulation. This Supplement constitutes “supplementary listing particulars” for the purpose of listing on the Global Exchange Market of Euronext Dublin. These supplementary listing particulars have been approved by Euronext Dublin for the purposes of listing on its Global Exchange Market.
Terms defined in the Base Prospectus have the same meaning when used in this Supplement. This Supplement is supplemental to, and shall be read in conjunction with, the Base Prospectus and any other supplements to the Base Prospectus issued by RBC.

RBC accepts responsibility for the information contained in this Supplement. To the best of the knowledge of RBC, the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

The purpose of this Supplement is:

(i) to incorporate by reference in the Base Prospectus the Issuer’s unaudited interim condensed consolidated financial statements (the “First Quarter 2023 Unaudited Interim Condensed Consolidated Financial Statements”), together with the Management’s Discussion and Analysis (the “First Quarter 2023 MD&A”) for the three month period ended January 31, 2023 set out in the Issuer’s First Quarter 2023 Report to Shareholders (the “First Quarter 2023 Report to Shareholders”). The remainder of the First Quarter 2023 Report to Shareholders is either covered elsewhere in the Base Prospectus or is not relevant for investors;

(ii) following the publication of the First Quarter 2023 Report to Shareholders, to update the statement of no significant change of the Issuer; and

(ii) following the publication of the First Quarter 2023 Report to Shareholders, to update paragraph 3 of the section entitled “General Information” in the Base Prospectus regarding governmental, legal or arbitration proceedings which may have, or have had, a significant effect on the financial position or profitability of the Issuer or of the Issuer and its subsidiaries taken as a whole.

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Base Prospectus by this Supplement and (b) any other statement in, or incorporated by reference in, the Base Prospectus, the statements in (a) above will prevail.

Save as disclosed in this Supplement or those sections of the First Quarter 2023 Report to Shareholders incorporated by reference in the Base Prospectus by virtue of this Supplement, no significant new factor, material mistake or material inaccuracy relating to the information included in the Base Prospectus which may affect the assessment of Securities issued under the Programme has arisen or been noted, as the case may be, since the approval by the Central Bank of Ireland and Euronext Dublin of the 3rd Supplementary Prospectus dated December 20, 2022.

With respect to an offer of Securities to the public, investors who have agreed to purchase or subscribe for securities before this Supplement is published have the right, exercisable before the end of the period of three working days beginning with the working day after the date on which this Supplement was published, to withdraw their acceptances. This right to withdraw will expire by close of business on March 10, 2023. Investors who decide to exercise their right of withdrawal may do so by notifying the banks and financial entities that have agreed to place the Securities and that are identified in the applicable Final Terms of the Securities.
DOCUMENTS INCORPORATED BY REFERENCE

RBC’s First Quarter 2023 Unaudited Interim Condensed Consolidated Financial Statements, together with the First Quarter 2023 MD&A, set out on pages 2 through 67 (excluding page 46 of the same) of the First Quarter 2023 Report to Shareholders are by virtue of this Supplement incorporated in, and form part of, the Base Prospectus. The remainder of the First Quarter 2023 Report to Shareholders is either covered elsewhere in the Base Prospectus or is not relevant for investors.

The First Quarter 2023 Report to Shareholders, which includes the First Quarter 2023 Unaudited Interim Condensed Consolidated Financial Statements and First Quarter 2023 MD&A, is available for viewing at:

First Quarter 2023 Report to Shareholders
https://www.rbc.com/investor-relations/_assets-custom/pdf/2023q1_report.pdf

For the avoidance of doubt, any document incorporated by reference in the First Quarter 2023 Report to Shareholders, including the First Quarter 2023 Unaudited Interim Condensed Consolidated Financial Statements or the First Quarter 2023 MD&A, shall not form part of this Supplement.

The First Quarter 2023 Report to Shareholders and copies of this Supplement are available for inspection from https://www.rbc.com/investor-relations/european-senior-notes-program.html. Certain of the documents incorporated by reference in the Base Prospectus or this Supplement may be viewed by accessing the Issuer’s disclosure documents through the Internet at the Canadian System for Electronic Document Analysis and Retrieval at http://www.sedar.com (an internet based securities regulatory filing system). Please note that websites and URLs referred to herein do not form part of this Supplement or the Base Prospectus.

STATEMENT OF NO SIGNIFICANT CHANGE

Since January 31, 2023, the last day of the financial period in respect of which the most recent unaudited interim condensed consolidated financial statements of the Issuer have been published, there has been no significant change in the financial performance or financial position of the Issuer and its subsidiaries taken as a whole.

AMENDMENT TO STATEMENT REGARDING GOVERNMENTAL, LEGAL OR ARBITRATION PROCEEDINGS

Paragraph 3 of the section entitled “General Information” on page 714 of the Base Prospectus is hereby deleted in its entirety and replaced with the following:

“Other than (i) the matters disclosed under the subsection entitled “Tax examinations and assessments” in Note 22 of the 2022 Audited Consolidated Financial Statements set out on page 216 of the Issuer’s 2022 Annual Report, (ii) the legal and regulatory matters disclosed (with the exception of the subsection entitled “Other matters”) in Note 25 of the 2022 Audited Consolidated Financial Statements set out on pages 219 and 220 of the Issuer’s 2022 Annual Report and (iii) the legal and regulatory matters disclosed in the subsection entitled “Legal and Regulatory Matters” in Note 12 of the Issuer’s First Quarter 2023 Unaudited Interim Condensed Consolidated Financial Statements set out on page 65 of the Issuer’s First Quarter 2023 Report
to Shareholders and in each case incorporated by reference herein, there are no, nor have there been, any governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which the Issuer is aware) during the twelve months prior to the date of this document which may have, or have had in the recent past, individually or in the aggregate, a significant effect on the financial position or profitability of the Issuer or of the Issuer and its subsidiaries taken as a whole."